Neovision Capital

The firm's stated mandate spans the full venture lifecycle, from seed and start-up rounds through expansion and late-stage growth. This positions Neovision Capital to enter at formation and follow on through later fundraises, though specific check-size ranges or stage concentrations have not been publicly disclosed.

Sourcing mechanics are not documented in the firm's public materials. Given the Shanghai base and generalist venture strategy, typical channels would include domestic incubators, university spin-out networks, and local government-guided funds — but no primary evidence confirms Neovision Capital's specific origination approach.

The firm has not published co-investment policies or preferences. While many Chinese venture managers syndicate rounds, Neovision Capital's public record provides no guidance on whether it leads rounds, follows, or shares allocations with domestic or international co-investors.

No sector-specific focus areas are declared on the firm's website. The venture-generalist label suggests broad exposure across technology, consumer, and potentially healthcare verticals common among China-domiciled funds, but any such attribution remains unverified.

Neovision Capital has not disclosed its GP bench or investment committee structure. No named principals are available through regulatory filings, press coverage, or the firm's own digital presence, leaving the leadership team entirely opaque to outside allocators.